On March 19, 2015 Coronado Biosciences reported the execution of an exclusive license agreement with NeuPharma, Inc. to develop and commercialize novel irreversible, 3rd Generation EGFR inhibitors on a worldwide basis outside of certain Asian countries. The program is currently in pre-clinical development (Press release, Coronado Biosciences, MAR 19, 2015, View Source [SID:1234502338]). Under the terms of the agreement, Coronado will pay NeuPharma an up-front licensing fee as well as make development and sales-based milestone payments and will pay a tiered single digit royalty on net sales. Schedule your 30 min Free 1stOncology Demo! Dr. Lindsay A. Rosenwald, Chairman and CEO stated, "Targeting EGFR mutations with 3rd generation covalently-bound inhibitors has demonstrated clear activity in patients with Non-Small Cell Lung Cancer (NSCLC) carrying specific EGFR mutations while avoiding the toxicity seen with first and second generation inhibitors that also target wild type EGFR, which typically results in dose limiting side effects such as diarrhea and rash. We believe the inhibitors developed by NeuPharma may have distinct advantages even over the current 3rd generation compounds in this class. NeuPharma has a portfolio of these inhibitors, the most advanced of which could reach the clinic in the first half of 2016." Dr. Rosenwald continued, "We are very excited to add this novel program to our growing portfolio. Since restructuring the Company a little over a year ago, our goal has been to build a diverse portfolio of subsidiary companies and product opportunities, and we believe this program adds another important piece to the overall business plan."
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
"We are very pleased to be collaborating with Coronado. This collaboration will greatly accelerate the global development and commercialization of our 3rd Generation EGFR inhibitors discovered using our structure-based drug design platform", stated Shawn Qian, Ph.D., President and CEO of NeuPharma.